Suppr超能文献

葡萄膜炎性黄斑水肿的治疗干预措施:一项系统评价和荟萃分析。

Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis.

作者信息

Karim Rushmia, Sykakis Evripidis, Lightman Susan, Fraser-Bell Samantha

机构信息

Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia.

出版信息

Clin Ophthalmol. 2013;7:1109-44. doi: 10.2147/OPTH.S40268. Epub 2013 Jun 11.

Abstract

BACKGROUND

Uveitic macular edema is the major cause of reduced vision in eyes with uveitis.

OBJECTIVES

To assess the effectiveness of interventions in the treatment of uveitic macular edema.

SEARCH STRATEGY

Cochrane Central Register of Controlled Trials, Medline, and Embase. There were no language or data restrictions in the search for trials. The databases were last searched on December 1, 2011. Reference lists of included trials were searched. Archives of Ophthalmology, Ophthalmology, Retina, the British Journal of Ophthalmology, and the New England Journal of Medicine were searched for clinical trials and reviews.

SELECTION CRITERIA

Participants of any age and sex with any type of uveitic macular edema were included. Early, chronic, refractory, or secondary uveitic macular edema were included. We included trials that compared any interventions of any dose and duration, including comparison with another treatment, sham treatment, or no treatment.

DATA COLLECTION AND ANALYSIS

Best-corrected visual acuity and central macular thickness were the primary outcome measures. Secondary outcome data including adverse effects were collected.

CONCLUSION

More results from randomized controlled trials with long follow-up periods are needed for interventions for uveitic macular edema to assist in determining the overall long-term benefit of different treatments. The only intervention with sufficiently robust randomized controlled trials for a meta-analysis was acetazolamide, which was shown to be ineffective in improving vision in eyes with uveitic macular edema, and is clinically now rarely used. Interventions showing promise in this disease include dexamethasone implants, immunomodulatory drugs and anti-vascular endothelial growth-factor agents. When macular edema has become refractory after multiple interventions, pars plana vitrectomy could be considered. The disease pathophysiology is uncertain and the course of disease unpredictable. As there are no clear guidelines from the literature, interventions should be tailored to the individual patient.

摘要

背景

葡萄膜炎性黄斑水肿是葡萄膜炎患者视力下降的主要原因。

目的

评估治疗葡萄膜炎性黄斑水肿的干预措施的有效性。

检索策略

Cochrane对照试验中心注册库、Medline和Embase。检索试验时无语言或数据限制。数据库最后一次检索时间为2011年12月1日。检索纳入试验的参考文献列表。检索《眼科学档案》《眼科学》《视网膜》《英国眼科学杂志》和《新英格兰医学杂志》以获取临床试验和综述。

入选标准

纳入任何年龄和性别的患有任何类型葡萄膜炎性黄斑水肿的参与者。包括早期、慢性、难治性或继发性葡萄膜炎性黄斑水肿。我们纳入了比较任何剂量和疗程的任何干预措施的试验,包括与另一种治疗、假治疗或不治疗进行比较。

数据收集与分析

最佳矫正视力和中心黄斑厚度是主要结局指标。收集包括不良反应在内的次要结局数据。

结论

对于葡萄膜炎性黄斑水肿的干预措施,需要更多来自长期随访的随机对照试验的结果,以帮助确定不同治疗的总体长期益处。唯一有足够强有力的随机对照试验可用于荟萃分析的干预措施是乙酰唑胺,结果显示其对改善葡萄膜炎性黄斑水肿患者的视力无效,目前临床上很少使用。在这种疾病中显示出前景的干预措施包括地塞米松植入物、免疫调节药物和抗血管内皮生长因子药物。当黄斑水肿在多次干预后变得难治时,可以考虑行玻璃体切除术。该病的病理生理机制尚不确定,疾病进程不可预测。由于文献中没有明确的指南,干预措施应根据个体患者进行调整。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b515/3685443/cb00cdee7fff/opth-7-1109f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验